Tocilizumab-Induced Dermatosis in a Patient With Rheumatoid Arthritis

被引：3

作者：

Babkoor, Doaa ^{[1
]}

Alshuqayfi, Abeer ^{[2
]}

Alshegaifi, Nada ^{[2
]}

Bamosa, Hanan ^{[2
]}

Alsaid, Maryam ^{[2
]}

Alkinani, Athba ^{[2
]}

Algozi, Shahad ^{[2
]}

AlZaidi, Reema ^{[3
]}

Alahmadi, Lina ^{[4
]}

Hafiz, Waleed A. ^{[4
,5
]}

机构：

[1] Alnoor Specialist Hosp, Dept Dermatol, Mecca, Saudi Arabia

[2] Umm Al Qura Univ, Coll Med, Al Qunfudah, Saudi Arabia

[3] Taif Univ, Coll Med, Taif, Saudi Arabia

[4] Alnoor Specialist Hosp, Dept Med, Mecca, Saudi Arabia

[5] Umm Al Qura Univ, Coll Med, Mecca, Saudi Arabia

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2022年 / 14卷 / 12期

关键词：

drug-induced reactions; dermatologic manifestations; dermatosis; tocilizumab; rheumatoid arthriitis;

D O I：

10.7759/cureus.32967

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Rheumatoid arthritis is a chronic systemic autoimmune disease that results in symmetrical inflammatory polyarthritis with extra-articular involvement, including skin manifestations. It targets the lining of the synovial membranes and is treated with disease-modifying antirheumatic drugs. If left untreated, it leads to increased morbidity, mortality, and socioeconomic burdens. Tocilizumab is a humanized monoclonal antibody that binds to interleukin-6 receptors and is used to treat rheumatoid arthritis in patients with inadequate response to conventional synthetic therapy. This medication can cause adverse dermatologic events, such as urticaria, pruritus, and mild maculopapular rash. In this case, we report a 39-year-old woman with rheumatoid arthritis who developed tocilizumab-induced dermatosis.

引用

页数：4

共 10 条

[1]

Borham L, 2021, Skills in rheumatology, P83

[2]

Izquierdo J H, 2012, Case Rep Rheumatol, V2012, P517424, DOI 10.1155/2012/517424

[3] Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid Arthritis [J].

Jones, Graeme ;

Ding, Changhai .

CLINICAL MEDICINE INSIGHTS-ARTHRITIS AND MUSCULOSKELETAL DISORDERS, 2010, 3 :81-89

[4] Skin manifestations of rheumatoid arthritis [J].

Lora, Viviana ;

Cerroni, Lorenzo ;

Cota, Carlo .

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2018, 153 (02) :243-255

[5]

Omair MA, 2020, JAMA NETW OPEN, V3, P344

[6] Tocilizumab-Induced Psoriasiform Rash in Rheumatoid Arthritis [J].

Palmou-Fontana, Natalia ;

Sanchez Gavino, Juan Antonio ;

McGonagle, Dennis ;

Garcia-Martinez, Eva ;

de Onzono Martin, Luis Iniguez .

DERMATOLOGY, 2014, 228 (04) :311-313

[7] Rheumatoid arthritis [J].

Smolen, Josef S. ;

Aletaha, Daniel ;

Barton, Anne ;

Burmester, Gerd R. ;

Emery, Paul ;

Firestein, Gary S. ;

Kavanaugh, Arthur ;

McInnes, Iain B. ;

Solomon, Daniel H. ;

Strand, Vibeke ;

Yamamoto, Kazuhiko .

NATURE REVIEWS DISEASE PRIMERS, 2018, 4

[8] Paradoxical cutaneous reactions associated with tocilizumab therapy [J].

Sparsa, L. ;

Afif, N. ;

Bularca, S. ;

Fricker, A. ;

Thiebault, S. ;

Dahan, E. ;

Wendling, D. ;

Sibilia, J. ;

Ardizzone, M. .

REVUE DE MEDECINE INTERNE, 2014, 35 (09) :613-616

[9] Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial [J].

Villiger, Peter M. ;

Adler, Sabine ;

Kuchen, Stefan ;

Wermelinger, Felix ;

Dan, Diana ;

Fiege, Veronika ;

Butikofer, Lukas ;

Seitz, Michael ;

Reichenbach, Stephan .

LANCET, 2016, 387 (10031) :1921-1927

[10] Tocilizumab-Induced Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in Adult-Onset Still Disease [J].

Zuelgaray, Elina ;

Domont, Fanny ;

Peiffer-Smadja, Nathan ;

Saadoun, David ;

Cacoub, Patrice .

ANNALS OF INTERNAL MEDICINE, 2017, 167 (02) :141-U142

← 1 →